For most of the industry's existence, pharmaceuticals have preliminary consisted of simple, fast-acting chemical compounds that are dispensed orally or as injectables. During the last three decades, however, formulations that control the rate and target specific area of the body for treatment have become increasingly common. Nowadays, nanosuspension technology with mucoadhesive principle comes into front for achieving to increased uptake and accumulation of drug in affected region of targeted organ. In the present study, preparation of nanosuspension for famotidine and curcumin by solvent evaporation technique as well as media milling technique using stabilizers was initially adopted. Formulation and process variables were identified based on particle size analysis and in vitro drug release. Optimized nanosuspension was characterized by particle size analysis, zeta potential determination, scanning electron microscopy (SEM). In vivo and ex-vivo study of optimized mucoadhesive nanosuspension was performed using rat stomach and compared with marketed suspension for healing of peptic ulcer.